Innovation and Industrial Innovation and Industrial Development in Health: Prospection for Action Coordination: Presidency of FIOCRUZ An Agreenment between.

Apresentação em tema: "Innovation and Industrial Innovation and Industrial Development in Health: Prospection for Action Coordination: Presidency of FIOCRUZ An Agreenment between."— Transcrição da apresentação:

1 Innovation and Industrial Innovation and Industrial Development in Health: Prospection for Action Coordination: Presidency of FIOCRUZ An Agreenment between FIOCRUZ and FIOTEC – Ministry of Health

2 The Country’s Situation TheHealth System The Country’s Situation The Health System National Health System/ SUS (1988/ 1990) – Universalization, decentralization e hierarchization – Federal Level: coordination, regulation and financing Highly influential over the entire health system – Ex: Medicine program (generics), immunizations, blood control, blood derived products, investments (REFORSUS), services, etc. A Strong Demand for Health Services and Products

3 Health Industrial Complex Pharmaceutical Industry Drugs / Medications Medical equipment and medical products industry Non-electric/electronic devices Eletric/electronic devices Prosthetics and orthotics Consumer goods Vaccine Industry Blood-derived products Diagnostic Reagents Industry Public Private Philanthtopy Service Sector Product Manufacturing Industries Source: ECIB-COMPLEXO DA SAÚDE, 2002 G O V E R N M E N T - P R O M O T I O N A N D R E G U L A T I O N

4 Competition in the Industry Downfall in Competitiveness in the 90’s Growing gap between supply capacity and social needs Outburst of the Trade Deficit – from US$ 750 million to US$ 3,5 billion – Medications: US$ 860 million – Drugs: US$ 1,250 million – Vaccines: US$ 121 million – Diagnostic reagents: US$ 126 million – Material and Equipment: US$ 870 million Major Determinant: domestic (in)capacity to produce innovation in terms of health

5 Risks and Prospects Risks Product re-specialization caused by globalization (products with low aggregate value) Broadening of the technological gap and loss of competitiveness Vulnerability of the Brazilian economy and social policy Health policy highly and incresingly dependent on imports – Present estimate: R$ 12 billion/year

6 Prospects Favorable political environment to implement socially oriented development policies Ex: BNDES Seminar on the Health Industrial Complex; The launching seminar of the Innovation Project ; The Forum on Competitiveness in the Pharmaceutic Production Chain and in Biotechnology The new Lews: “Innovaton” and “PPP” Evidence of significant space to move foward: – The size of national health needs – The structuring process of the Health System (SUS): the inducing role of the State – The relevant deficit with developing countries Major Instruments: – Industrial and innovation-oriented policies – Health policies: the use of the State’s purchase capacity, coordination and induction

7 Prospects The establishment of a thorough tie between industrial, innovation and social policies – Niche identification, innovation networks and anchors in the different segments of the complex – Evaluation of health needs on short, mid and long terms – Strengthening of the partnerships between the public and the private spheres Strengthening of local innovation bases on a policy destined to reduce national inequalities – Induction of local productive arrangements in health – Use of local habilities and the formation of innovation networks in health

8 Objectives of the Study To propose a mid and long term plan for innovation and development in health To serve as subsidy for the formulation and the establishment of innovation and industrial policies for manufacturing activities in health To identify and promote competitive niches and windows of opportunities for Brazil To develop a discussion over the matter and to define priorities as to the State, the production sector and the University (“Triple Helix”)(Brazilian brand-new “Triple Helix plus”). General Objectives

9 Objectives of the Study To evaluate the world technological frontier in terms of health To evaluate the Brazil’s capacity in innovation in health as compared to the rest of the world To evaluate long term needs of development and innovation in health To serve as subsidy for policies concerning the competitiveness of domestic manufacturers in terms of technology and management To develop terms of commitment between the State and the manufacturers with the aim of expanding competitiveness and innovation Specific Objectives

10 Selected Sectors and Areas Vertical Studies – Drugs and Medications – Vaccines – Diagnostic Reagents Priorities Defined by Health Needs Horizontal Studies – Disease Burden – Intelectual Property

11 Methodology: stressing the establishment of policies Projects developed for different priority sectors and areas by specialized consultants Discussion with specialist technical groups about the projects’ contributions (Workshops) Discussion with public administrators aiming at defining policies and priorities for development and innovation in health Dissemination of the results to the State and to society Signing of the Terms of Commitment for development and innovation in health

12 Institutional Partnerships Ministry of Health – Minister Cabinet, Executive Secretariat, Health Surveillance Secretariat, Science, Technology and Health Products Secretariat, SAS, ANVISA, ANS, FUNASA Ministry of Science and Technology and Ministry of Education – FINEP, CNPq, CAPES Ministry of Development, Industry and Commerce – BNDES Brazil’s Private Industry Public Manufacturers of Goods and Services in Health Science and Technology in Health Community International Institutions

13 Vaccine Studies Ministry of Health / Financing Agencies / Manufacturers Coordenation FGV (Dr. José Castanhar) UFRJ – Chem Department (Dr. José Vítor) International Consultant (Dra. Julie Milstien) Institution November 2003 October 2003 July 2003 Report 11/05 09/29 09/12 Held in June 2003 Workshop October 2003 09/15 08/15 Concluded May 2003 Study Beginning December 2003 Terms of Commitment Includes negotiation with Ministries and Financing Agencies Development of Propositions Report with majorconclusions.conclusions. Managerial Capacity of Public Manufacturers Report with major conclusions. conclusions. Prospection of Domestic Capacity of R&D in Vaccines International Prospection Studies of the World Market Observations Studies/Stages Present Stage Dr. Manuel Limonta (Cuba) September 2003 08/1107/31 Technological Capacity of Vaccine Production Report with major conclusions. conclusions. Report with major conclusions. conclusions.

14 Estudos Horizontais ENSP/ FIOCRUZ (Dr.Jorge Bermudez) ENSP/ FIOCRUZ (Dra.Joyce Schramm) Institution July 2004 June 2004 Report September 2004 August 2004 Workshop March 2004 Study - The TRIPS Agreement and its impact on public health and innovation Intelectual Property - 2003-2015 Projections Disease Burden – Epidemiology / Demographics Observations Studies/Stages Disease Burden – aims at contributing to identify the priorities of scientific and technological development of health products and research from 2003 to 2015, considering the morbidity/mortality rates Intelectual Property – Considering international agreements at the World Commerce Organization (TRIPS), it intends to serve as a subsidy for the definition of politics for the development, management and manufacturing of public health products in the country. Estágio Atual

15

16 PROGRAMA INOVACINA Formulação e Estado Atual Setembro de 2006 José R. Carvalheiro Projeto Inovação em Saúde/ FIOCRUZ jrcarval@fiocruz.br

17 MARCOS ESSENCIAIS NO DESENVOLVIMENTO 2002: Projeto Inovação em Saúde: vacinas, medicamentos e reagentes 2003: Estudo de vacinas: metodologia, a hélice tripla, “Inovacina”, livro 2004: Fóruns Competitividade (MDIC), Cadeia Farmacêutica, Biotecnologia (GT de Saúde Humana), aceita “Inovacina” como base 2005: documento que define “Política Brasileira de Desenvolvimento Industrial” (ABDI, CGEE); atualizar o “Inovacina”, apreciação por especialistas, Seminário para definir proposta. [DOCUMENTO]

18 PROGRAMA NACIONAL DE COMPETITIVIDADE EM VACINAS (INOVACINA) 4 COMPONENTES: A) Definição de políticas e organização da produção. B) Modernização do parque produtivo. C) Avaliação e regulação (Anvisa) (Ensaio Clínico/não clínico). D) Desenvolvimento e inovação (Translational).

19 Legislação encaminhada (2006) Maio (2006) Portarias GM / MS 972 e 973: cria “Inovacina” e a “Câmara Técnica de Imunobiológicos” Julho (2006) no Fórum de Competitividade de Biotecnologia: “Estratégia Nacional de Biotecnologia” e “Política de Desenvolvimento da Bioindústria”, acolhendo a essência do “Inovacina”; os 4 Ministros (MDIC, Saúde, Agricultura e C&T) assinam Exposição de Motivos ao Presidente da República com Minuta de Decreto; cria um “Comitê Nacional de Biotecnologia” coordenado pelo MDIC com 14 representantes de ministérios.

20 Novas Prioridades (Maio/Julho 2006) Até 3 anos Pentavalente (DTP/HB+Hib) Raiva em cultura celular Meningite Meningococica, C conjugada. Leishamaniose canina Vacina DNA para uso terapêutico da tuberculose (câncer de pescoço e cabeça) Raiva para uso canino em cultura de tecidos Gripe Pandêmica – aviária

21 Até 5 anos Meningite Meningococica, B + C conjugada Febre Amarela Inativada Streptococcus pneumoniae HPV Poliomielite inativada DTPa (pertussis acelular) MMR/Varicela Hepatite A Meningite Meningococica B

22 Até 10 anos Rotavírus Meningite A conjugada DTPa/HB + Hib MMR/ Varicela Meningite C conj + Hib + pneumococos HBV/HAV

23 Até 15 anos Leishmaniose

24 Prazo Indefinido Malária Dengue HIV/AIDS Leptospirose Hepatite C Xistosoma Varíola Tuberculose

25 Outros Necator Adjuvantes Soros hiperimunes